This Site Is Intended for US Healthcare Professionals Only
3 INDICATIONS VOQUEZNA® (vonoprazan) is indicated for the healing of all grades of Erosive Esophagitis in adults Read More

The first FDA-approved PCAB1

VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) that may selectively concentrate in the parietal cells in both the resting and stimulated states, suppressing acid by inhibiting the binding of potassium ions to the acid pump.1

Image shows how a PCAB suppresses acid by inhibiting the binding of potassium ions to the acid pump
The clinical significance of these mechanistic differences has not been established.

Features of vonoprazan include1:

  • Acid is not required for activation
  • Binds to active acid pumps in a noncovalent and reversible manner
  • Long half-life (7.7-7.9 hours) *

*7.7 hours with 10‑mg dose and 7.9 hours with 20‑mg dose.

The novel mechanism of action behind PCABs

Learn how this unique acid suppressant works

SEE EROSIVE GERD DATASEE NON-EROSIVE GERD DATA